Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Rating) Chairman John F. Crowley sold 10,468 shares of Amicus Therapeutics stock in a transaction that occurred on Thursday, December 15th. The shares were sold at an average price of $12.15, for a total transaction of $127,186.20. Following the sale, the chairman now directly owns 791,454 shares of the company’s stock, valued at approximately $9,616,166.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Amicus Therapeutics Stock Down 3.8 %
NASDAQ:FOLD traded down $0.47 during trading hours on Monday, reaching $11.76. The company’s stock had a trading volume of 1,532,162 shares, compared to its average volume of 3,103,414. The company has a market capitalization of $3.30 billion, a P/E ratio of -12.80 and a beta of 0.90. Amicus Therapeutics, Inc. has a 12 month low of $5.91 and a 12 month high of $12.96. The company has a debt-to-equity ratio of 2.95, a quick ratio of 2.70 and a current ratio of 2.78. The stock has a 50 day moving average price of $11.21 and a two-hundred day moving average price of $10.87.
Amicus Therapeutics (NASDAQ:FOLD – Get Rating) last released its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.07. Amicus Therapeutics had a negative net margin of 81.65% and a negative return on equity of 123.94%. The business had revenue of $81.69 million for the quarter, compared to analyst estimates of $84.55 million. Equities analysts predict that Amicus Therapeutics, Inc. will post -0.78 EPS for the current fiscal year.
Analysts Set New Price Targets
FOLD has been the subject of several research analyst reports. StockNews.com raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday. Morgan Stanley lifted their price target on shares of Amicus Therapeutics from $14.00 to $15.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 8th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $14.67.
Hedge Funds Weigh In On Amicus Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of FOLD. Pictet Asset Management SA grew its holdings in Amicus Therapeutics by 442.0% in the third quarter. Pictet Asset Management SA now owns 3,485,302 shares of the biopharmaceutical company’s stock worth $36,387,000 after purchasing an additional 2,842,220 shares during the last quarter. State Street Corp grew its holdings in shares of Amicus Therapeutics by 16.6% during the second quarter. State Street Corp now owns 13,918,315 shares of the biopharmaceutical company’s stock valued at $149,483,000 after buying an additional 1,983,752 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund grew its holdings in shares of Amicus Therapeutics by 50.8% during the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 2,626,600 shares of the biopharmaceutical company’s stock valued at $27,422,000 after buying an additional 884,400 shares during the last quarter. Woodline Partners LP purchased a new stake in shares of Amicus Therapeutics during the first quarter valued at $8,185,000. Finally, Candriam S.C.A. purchased a new stake in shares of Amicus Therapeutics during the second quarter valued at $9,009,000.
About Amicus Therapeutics
(Get Rating)
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data.
Featured Stories
- Get a free copy of the StockNews.com research report on Amicus Therapeutics (FOLD)
- Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
- Madrigal Pharmaceuticals Stock Is Up 200% In One Day, Here’s Why
- Four Profitable RV Stocks To Ride Out Recession
- Can Boeing Stock Soar in 2023?
- How Do Chipmakers Stack Up When It Comes To Growth?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Amicus Therapeutics, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Amicus Therapeutics wasn’t on the list.
While Amicus Therapeutics currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we’ll send you MarketBeat’s list of seven best retirement stocks and why they should be in your portfolio.
Enter your email address below and we’ll send you MarketBeat’s guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
As Featured By:
326 E 8th St #105, Sioux Falls, SD 57103
contact@marketbeat.com
(844) 978-6257
© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.
